1. Home
  2. SLXN vs BQ Comparison

SLXN vs BQ Comparison

Compare SLXN & BQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • BQ
  • Stock Information
  • Founded
  • SLXN 2008
  • BQ 2008
  • Country
  • SLXN Israel
  • BQ China
  • Employees
  • SLXN N/A
  • BQ 241
  • Industry
  • SLXN
  • BQ Other Specialty Stores
  • Sector
  • SLXN
  • BQ Consumer Discretionary
  • Exchange
  • SLXN NYSE
  • BQ Nasdaq
  • Market Cap
  • SLXN 7.3M
  • BQ 7.1M
  • IPO Year
  • SLXN N/A
  • BQ 2020
  • Fundamental
  • Price
  • SLXN $0.83
  • BQ $2.85
  • Analyst Decision
  • SLXN Strong Buy
  • BQ
  • Analyst Count
  • SLXN 1
  • BQ 0
  • Target Price
  • SLXN $5.00
  • BQ N/A
  • AVG Volume (30 Days)
  • SLXN 784.5K
  • BQ 222.0K
  • Earning Date
  • SLXN 08-21-2025
  • BQ 07-29-2025
  • Dividend Yield
  • SLXN N/A
  • BQ N/A
  • EPS Growth
  • SLXN N/A
  • BQ N/A
  • EPS
  • SLXN N/A
  • BQ N/A
  • Revenue
  • SLXN N/A
  • BQ $81,208,354.00
  • Revenue This Year
  • SLXN N/A
  • BQ N/A
  • Revenue Next Year
  • SLXN N/A
  • BQ N/A
  • P/E Ratio
  • SLXN N/A
  • BQ N/A
  • Revenue Growth
  • SLXN N/A
  • BQ N/A
  • 52 Week Low
  • SLXN $0.58
  • BQ $1.62
  • 52 Week High
  • SLXN $41.85
  • BQ $9.89
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • BQ 56.60
  • Support Level
  • SLXN N/A
  • BQ $2.01
  • Resistance Level
  • SLXN N/A
  • BQ $9.89
  • Average True Range (ATR)
  • SLXN 0.00
  • BQ 0.87
  • MACD
  • SLXN 0.00
  • BQ 0.07
  • Stochastic Oscillator
  • SLXN 0.00
  • BQ 12.67

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

Share on Social Networks: